Ordenar por:
95 productos
95 productos
NORDET (NORETISTERONA / ETINILESTRADIOL)
Comparable a: Nordet
Sustancia activa: Noretisterona / Etinilestradiol
Presentación: Caja con 21 grageas
Laboratorio: Wyeth
Origen: México
Nordet es un medicamento anticonceptivo oral combinado que se utiliza para prevenir el embarazo. La combinación de noretisterona y etinilestradiol actúa inhibiendo la ovulación, espesar el moco cervical y modificar el endometrio, reduciendo la probabilidad de concepción cuando se usa de forma correcta según indicación médica.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
NORISTERAT (NORETISTERONA) 200 mg / 1 mL
Comparable a: Noristerat
Sustancia activa: Noretisterona
Concentración: 200 mg / 1 mL
Presentación: Caja con 1 ampolleta de 1 mL de solución inyectable
Laboratorio: Bayer de Mexico
Origen: México
Noristerat es un medicamento anticonceptivo hormonal inyectable de acción prolongada que se utiliza para prevenir el embarazo. La noretisterona actúa suprimiendo la ovulación, espesando el moco cervical y modificando el endometrio, lo que reduce la probabilidad de concepción cuando se administra bajo supervisión médica.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
RADIANCE (DROSPIRENONA / ETINILESTRADIOL)
Comparable a: Radiance
Sustancia activa: Drospirenona / Etinilestradiol
Presentación: Caja con 28 tabletas
Laboratorio: Liomont
Origen: México
Este medicamento anticonceptivo oral combinado se utiliza para prevenir el embarazo. La combinación de drospirenona y etinilestradiol ayuda a inhibir la ovulación, espesar el moco cervical y modificar el endometrio, disminuyendo la probabilidad de concepción cuando se usa correctamente según indicación médica.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
Oral contraceptive with antiandrogenic effects antimineralocorticoid and also beneficial for women with fluid retention of hormone and the resulting symptoms and women with acne and seborrhea.
CONTRAINDICATIONS: Do not use oral contraceptives (COCs) in the presence of any of the situations listed below. Must cease immediately the use of prepared if any of them for the first time during his employment:
• Presence or history of thrombotic / thromboembolic arterial or venous (eg, deep vein thrombosis, pulmonary embolism, myocardial infarction) or stroke.
• Presence or history of prodrome of a thrombosis (eg transient ischemic attack, angina pectoris).
• History of migraine with focal neurological symptoms.
• Diabetes mellitus with vascular involvement.
• The presence of a serious risk factor or multiple risk factors for arterial or venous thrombosis may also constitute a contraindication (see Precautions).
• Presence or history of pancreatitis if it is associated with hypertriglyceridemia.
• Presence or history of severe liver disease while the liver function values have not returned to normal.
• severe renal insufficiency or acute renal failure.
• Presence or history of liver tumors (benign or malignant).
• known or suspected neoplasms, influenced by sex steroids (for example, of the genitals or the breasts).
• Undiagnosed vaginal bleeding.
• Pregnancy known or suspected.
• Hypersensitivity to the active substances or any of the excipients.
RESTRICTIONS OF USE DURING PREGNANCY AND LACTATION: RADIANCE is not indicated during pregnancy. If a woman becomes pregnant while taking RADIANCE, discontinue administration.
However, epidemiological studies on a large scale have not revealed an increased risk of birth defects in children of mothers who used COCs prior to pregnancy or a teratogenic effect when COCs were taken inadvertently during early pregnancy.
The available data on the use of Yasmin ® during pregnancy are too limited to draw conclusions about the negative effects of Yasmin ® about pregnancy, health of the fetus or the newborn. Not yet available relevant epidemiological data.
Breastfeeding can be affected by the AOC, as they may reduce the amount of milk and alter its composition and therefore should not be recommended in general the use of AOC until the mother has not completely stopped breastfeeding. Small amounts of contraceptive steroids and / or its metabolites can be eliminated by milk.
DOSAGE AND ADMINISTRATION:
How to take RADIANCE: If taken properly, COCs have a failure rate of about 1% per year. This failure rate may increase if you forget or incorrect taking the pill. The tablets should be taken in the order indicated on the package every day at about the same time, with a little liquid if necessary. It will take a tablet daily for 21 consecutive days. Each package will start back after an interval of 7 days without pills, which usually occur during a withdrawal bleed.The bleeding usually begin 2-3 days after taking the last pill, and you may not have finished where appropriate to start the next pack
YASMIN 24/4 (DROSPIRENONA / ETINILESTRADIOL)
Comparable a: Yasmin
Sustancia activa: Drospirenona / Etinilestradiol
Concentración: 3 mg / 0.03 mg por comprimido
Presentación: Caja con 28 comprimidos (24 activos + 4 inactivos)
Laboratorio: Bayer de Mexico
Origen: México
Yasmin 24/4 es un medicamento anticonceptivo oral combinado que se utiliza para prevenir el embarazo. La formulación de 24 comprimidos activos y 4 inactivos mantiene niveles hormonales más constantes durante el ciclo, ayudando a inhibir la ovulación, espesar el moco cervical y modificar el endometrio, reduciendo así la probabilidad de una concepción.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
YASMIN (DROSPIRENONA / ETINILESTRADIOL)
Comparable a: Yasmin
Sustancia activa: Drospirenona / Etinilestradiol
Concentración: 3 mg / 0.03 mg por tableta
Presentación: Caja con 21 tabletas
Laboratorio: BAYER
Origen: México
Yasmin es un medicamento anticonceptivo oral combinado que se utiliza para prevenir el embarazo. La drospirenona y el etinilestradiol actúan de manera conjunta para inhibir la ovulación, alterar el moco cervical y modificar el endometrio, reduciendo así la probabilidad de una concepción.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
Oral contraceptive with antiandrogenic effects antimineralocorticoid and also beneficial for women with fluid retention of hormone and the resulting symptoms and women with acne and seborrhea.
CONTRAINDICATIONS: Do not use oral contraceptives (COCs) in the presence of any of the situations listed below. Must cease immediately the use of prepared if any of them for the first time during his employment:
• Presence or history of thrombotic / thromboembolic arterial or venous (eg, deep vein thrombosis, pulmonary embolism, myocardial infarction) or stroke.
• Presence or history of prodrome of a thrombosis (eg transient ischemic attack, angina pectoris).
• History of migraine with focal neurological symptoms.
• Diabetes mellitus with vascular involvement.
• The presence of a serious risk factor or multiple risk factors for arterial or venous thrombosis may also constitute a contraindication (see Precautions).
• Presence or history of pancreatitis if it is associated with hypertriglyceridemia.
• Presence or history of severe liver disease while the liver function values have not returned to normal.
• severe renal insufficiency or acute renal failure.
• Presence or history of liver tumors (benign or malignant).
• known or suspected neoplasms, influenced by sex steroids (for example, of the genitals or the breasts).
• Undiagnosed vaginal bleeding.
• Pregnancy known or suspected.
• Hypersensitivity to the active substances or any of the excipients.
RESTRICTIONS OF USE DURING PREGNANCY AND LACTATION: YASMIN ® is not indicated during pregnancy. If a woman becomes pregnant while taking YASMIN ®, discontinue administration.
However, epidemiological studies on a large scale have not revealed an increased risk of birth defects in children of mothers who used COCs prior to pregnancy or a teratogenic effect when COCs were taken inadvertently during early pregnancy.
The available data on the use of Yasmin ® during pregnancy are too limited to draw conclusions about the negative effects of Yasmin ® about pregnancy, health of the fetus or the newborn. Not yet available relevant epidemiological data.
Breastfeeding can be affected by the AOC, as they may reduce the amount of milk and alter its composition and therefore should not be recommended in general the use of AOC until the mother has not completely stopped breastfeeding. Small amounts of contraceptive steroids and / or its metabolites can be eliminated by milk.
DOSAGE AND ADMINISTRATION:
How to take Yasmin ®: If taken properly, combined oral contraceptives have a failure rate of about 1% per year. This failure rate may increase if you forget or take the pill incorrectly. Thetablets should be taken in the order indicated on the package every day at about the same time with a little liquid if necessary. It will take one tablet daily for 21 consecutive days. Each package will start back after an interval of 7 days without pills, which usually occurs during a withdrawal bleed. The bleeding usually begin 2-3 days after taking the last tablet and may not have finished where appropriate to start the next pack.
PREMARIN (ESTRÓGENOS CONJUGADOS)
Comparable a: Premarin
Sustancia activa: Estrógenos conjugados
Concentración: 0.625 mg
Presentación: Caja con 42 tabletas
Laboratorio: Wyeth
Origen: México
Premarin es un medicamento hormonal indicado para el tratamiento de síntomas asociados a la menopausia, como bochornos, sudoración nocturna y alteraciones vaginales. También puede utilizarse en terapias hormonales sustitutivas y en ciertos trastornos ginecológicos, ayudando a restablecer el equilibrio hormonal.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
PROGYLUTON (ESTRADIOL / NORGESTREL)
Comparable a: Progyluton
Sustancia activa: Estradiol / Norgestrel
Presentación: Caja con 21 grageas
Laboratorio: Bayer de Mexico
Origen: México
Progyluton es un medicamento hormonal utilizado principalmente para regular el ciclo menstrual y como parte de terapias hormonales en casos de trastornos ginecológicos. La combinación de estradiol y norgestrel actúa sobre el sistema endocrino ayudando a equilibrar los niveles de hormonas femeninas.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
Reosvec 35 mg
Comparable a: Actonel
Sustancia activa: Risedronato
Concentración: 35 mg por gragea
Presentación: Caja con 4 grageas
Laboratorio: RAAM
Origen: México
Este medicamento se utiliza para el tratamiento y la prevención de la osteoporosis, ayudando a fortalecer los huesos y a reducir el riesgo de fracturas mediante la inhibición de la reabsorción ósea.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
PROVERA (MEDROXIPROGESTERONA)
Comparable a: Provera
Sustancia activa: Medroxiprogesterona
Concentración: 5 mg
Presentación: Caja con 24 tabletas
Laboratorio: PFIZER
Origen: México
Provera es un medicamento hormonal indicado para el tratamiento de diversos trastornos ginecológicos, como alteraciones del ciclo menstrual, amenorrea secundaria, sangrado uterino disfuncional y como parte de terapias hormonales. Actúa regulando el equilibrio hormonal y favoreciendo la función normal del endometrio.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
PREMARIN Crema Vaginal 43 g
Comparable a: Premarin
Sustancia activa: Estrógenos conjugados
Presentación: Tubo con 43 g de crema vaginal
Laboratorio: Wyeth
Origen: México
Este medicamento se utiliza para el tratamiento de los síntomas vaginales asociados a la menopausia, como sequedad, picazón y dolor durante las relaciones sexuales. Los estrógenos conjugados ayudan a restaurar la mucosa vaginal y mejorar la lubricación y elasticidad de los tejidos.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.
Contraindications: Suspected or confirmed pregnancy (see Restrictions of use during pregnancy and lactation).
Undiagnosed abnormal bleeding.
Suspected or confirmed estrogen-dependent neoplasia (eg endometrial cancer, endometrial hyperplasia).
History of active arterial thromboembolic disease (eg stroke, myocardial infarction) or deep thromboembolism (such as deep vein thrombosis, pulmonary embolism).
Dysfunction or active liver disease or chronic.
Known or suspected hypersensitivity to ingredients.
GENERAL PRECAUTIONS: Systemic absorption can occur with the use of vaginal cream with ECE. It must take into account the precautions and warnings associated with the oral treatment of ECE.
Fluid retention: Since estrogen / progestin may cause a degree of fluid retention in patients with conditions that can be influenced by this factor, such as cardiac or renal dysfunction, ensure careful observation when estrogens are prescribed.
In the study of health and osteoporosis, progestin and estrogen (HOPE), the mean increases from baseline in serum triglycerides after one year of treatment with CEE 0.625, 0.45 and 0.3 mg compared with placebo were 34.3,30.2 , 25.1, and 10.7 respectively.
Impaired liver function: Patients with impaired liver function may metabolize poorly estrogen / progestin.
History of cholestatic jaundice: For patients with a history of cholestatic jaundice associated with past use of estrogen or pregnancy, caution should be exercised, and in case of recurrence, medication should be discontinued.
You must select the lowest dose that controls your symptoms and should be discontinued ifsymptoms persist.
Usual dose range: ½ to two grams a day, vaginally, depending on the severity of the condition. Ensure that the discontinuation or reduction of medication takes place at intervals of 3 to 6 months.
Concomitant progestogen: The addition of a progestin during the administration of estrogenreduces the risk of endometrial hyperplasia and carcinoma, which has been associated withlong-term use of unopposed estrogen.
Morphological and biochemical studies of endometrium suggest that you need to manage for 10 to 14 days to provide maximum maturation of the endometrium in order to eliminate anyhyperplastic alteration.
Since progestogens are administered to protect against endometrial hyperplastic changes, patients without a uterus may not need a progestin. Administration should be cyclic (eg, three weeks of treatment and rest) and only for short-term therapy.
Patients should be reevaluated periodically to determine whether treatment of the symptomsis still necessary.
VAGITROL-V 10 ÓVULOS
Comparable a: Vagitrol-V
Sustancia activa: Acetónido de Fluocinolona, Metronidazol y Nistatina
Presentación: Caja con 10 óvulos vaginales
Laboratorio: BAYER
Origen: México
Este medicamento se utiliza para el tratamiento de infecciones vaginales, ayudando a aliviar síntomas como flujo, comezón, ardor e irritación, de acuerdo con la indicación médica.
El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.

{
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})"
x-init="document.addEventListener(`eurus:template--18441902293034__social_feeds_Cpq6fi:splide-ready`, () => {
$nextTick(() => {
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})
})"
>
{
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})"
x-init="document.addEventListener(`eurus:template--18441902293034__social_feeds_Cpq6fi:splide-ready`, () => {
$nextTick(() => {
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})
})"
>
{
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})"
x-init="document.addEventListener(`eurus:template--18441902293034__social_feeds_Cpq6fi:splide-ready`, () => {
$nextTick(() => {
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})
})"
>
{
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})"
x-init="document.addEventListener(`eurus:template--18441902293034__social_feeds_Cpq6fi:splide-ready`, () => {
$nextTick(() => {
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})
})"
>
{
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})"
x-init="document.addEventListener(`eurus:template--18441902293034__social_feeds_Cpq6fi:splide-ready`, () => {
$nextTick(() => {
if (window.innerWidth > 1024) {
$el.closest('.x-container-quickview-content').style.height = $el.offsetHeight + 'px'
}
})
})"
>